glp-1 inflammatory bowel disease Agonists, Gut Microbiome Dysbiosis & Inflammation GLP-1 IBD obesity "inflammatory bowel

These risks have become a key focus in the growing number of Wegovy-related lawsuits

Another study by van Bloemendaal and colleagues, conducted the following year, examined in greater detail how GLP-1 affects different phases of reward: wanting versus liking [2]

Al-Aly used these records to build what he calls an atlas of association, or a wide-ranging picture of the risks and benefits of the drugs throughout the body

Updated 2023

No consistent association was identified for other GLP-1 RAs 28,29,30,31 , and therefore, this conclusion should be interpreted cautiously

The risk-benefit balance may be less favourable for people near a normal BMI than for those who are clearly obese